GlassScriptPhysician profile
Chad M Hivnor
NPI 1477544476
$9,682.46
in general payments reported to CMS, 2019-2025
27 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,114 · 2020: $145 · 2021: $46.89 · 2022: $185 · 2023: $176 · 2024: $1,722 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis, INC | $6,467.52 | 2019 | |
| Lumenis Be INC | $1,319.98 | 2024 | M22 |
| Abbvie INC. | $837.56 | 2019-2024 | |
| Janssen Biotech, INC. | $174.10 | 2019-2023 | Tremfya |
| Therakos LLC | $127.19 | 2025 | Cellex, Uvadex |
| Genzyme Corporation | $108.98 | 2019-2024 | |
| Kyowa Kirin, INC. | $101.00 | 2025 | |
| Amgen INC. | $83.98 | 2022-2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $77.66 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $39.30 | 2019 | |
| Leo Pharma INC. | $34.50 | 2019-2025 | Adbry |
| Galderma Laboratories, L.P. | $31.79 | 2020-2021 | |
| Lilly USA, LLC | $27.30 | 2019-2020 | |
| Revance Therapeutics, INC. | $27.23 | 2024 | Daxxify |
| Krystal Biotech INC | $27.20 | 2024 | Vyjuvek |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $23.35 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.57 | 2025 | |
| Cipher Pharmaceuticals US LLC | $20.46 | 2025 | Spinosad, Natroba |
| Arcutis Biotherapeutics, INC. | $19.61 | 2024 | Zoryve |
| Pfizer INC. | $17.74 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.41 | 2019 | |
| Biofrontera INC. | $15.32 | 2019 | |
| Celgene Corporation | $13.46 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.34 | 2019 | |
| Sientra, INC. | $12.87 | 2020 | |
| Mylan Pharmaceuticals INC. | $11.95 | 2019 | |
| Genentech USA, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Hivnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.